Physician profile

Artrish Jefferson

Dallas, TX

NPI 1700405511

$607.05

in general payments reported to CMS, 2019-2025

5 companies · $338 in 2025

The $338 reported for 2025 was more than what a typical provider received nationally.

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$368.73
Education$238.32

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Abbott Laboratories $238.32 2024 Ensite
Astrazeneca Pharmaceuticals LP $166.08 2025 Wainua
Pfizer INC. $122.32 2025
Bridgebio Pharma, INC. $49.46 2025 Attruby
Abiomed $30.87 2024 Impella

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Artrish Jefferson

$607.05

in general payments reported 2019-2025

Years
2024-2025
Top company
Abbott Laboratories
Context
The $338 reported for 2025 was more than what a typical provider received nationally.

https://glasscript.com/doctor/11692955/artrish-jefferson

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Download CSV

The CSV has this whole record: totals, yearly figures, every listed company, payment types, and product associations.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.